JP2006528697A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528697A5
JP2006528697A5 JP2006533117A JP2006533117A JP2006528697A5 JP 2006528697 A5 JP2006528697 A5 JP 2006528697A5 JP 2006533117 A JP2006533117 A JP 2006533117A JP 2006533117 A JP2006533117 A JP 2006533117A JP 2006528697 A5 JP2006528697 A5 JP 2006528697A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical formulation
linker
hydrogen bond
immunomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006533117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/015313 external-priority patent/WO2004103301A2/en
Publication of JP2006528697A publication Critical patent/JP2006528697A/ja
Publication of JP2006528697A5 publication Critical patent/JP2006528697A5/ja
Withdrawn legal-status Critical Current

Links

JP2006533117A 2003-05-16 2004-05-14 イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置 Withdrawn JP2006528697A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47124703P 2003-05-16 2003-05-16
PCT/US2004/015313 WO2004103301A2 (en) 2003-05-16 2004-05-14 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents

Publications (2)

Publication Number Publication Date
JP2006528697A JP2006528697A (ja) 2006-12-21
JP2006528697A5 true JP2006528697A5 (https=) 2007-06-28

Family

ID=33476820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533117A Withdrawn JP2006528697A (ja) 2003-05-16 2004-05-14 イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置

Country Status (8)

Country Link
US (3) US7569554B2 (https=)
EP (1) EP1628531A4 (https=)
JP (1) JP2006528697A (https=)
KR (1) KR20060012622A (https=)
AU (1) AU2004241093B2 (https=)
CA (1) CA2526212C (https=)
MX (1) MXPA05012421A (https=)
WO (1) WO2004103301A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
AU2001294750C1 (en) * 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
ATE439135T1 (de) 2005-07-01 2009-08-15 Index Pharmaceuticals Ab Modulierung der reaktion auf steroide
AU2006266503B2 (en) 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2982679A1 (en) * 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
DK2596801T3 (en) * 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
AU2009259136B2 (en) * 2008-06-09 2014-09-25 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (en) * 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
CN102172359A (zh) * 2011-03-02 2011-09-07 张始状 腺苷与核苷组合在制备治疗肿瘤药物中的应用
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (https=) 1992-07-23 1995-04-01 Tri Clover Inc
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6581606B2 (en) * 1999-07-06 2003-06-24 The Rx Files Corporation Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response
EP2314693A3 (en) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1867718B1 (en) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
CA2398432C (en) 2000-01-26 2012-06-19 Hybridon, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
AU2001294750C1 (en) * 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
CA2456193A1 (en) * 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2512484A1 (en) * 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
JP4942646B2 (ja) * 2004-06-15 2012-05-30 イデラ ファーマシューティカルズ インコーポレイテッド 免疫賦活オリゴヌクレオチドマルチマー
US7498425B2 (en) * 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers

Similar Documents

Publication Publication Date Title
JP2006528697A5 (https=)
AU2004241093B2 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
JP2003535907A5 (https=)
EP2650369B1 (en) Novel synthetic agonists of TLR9
ES2908056T3 (es) Tratamiento del cáncer por agonistas del TLR9 con inhibidores del punto de control
US7786089B2 (en) Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
DE69427705T2 (de) Bor-cluster enthaltende nukleoside und oligonukleoside
JP2007509983A5 (https=)
RU2011135993A (ru) Новые синтетические агонисты tlr9
JP2009508842A5 (https=)
US20080279785A1 (en) Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
JP2012520298A (ja) Ｇａｂａに結合したアントラサイクリン−脂質複合体
HK1242199B (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors